JPRN-jRCT2080221423未知3 期
Phase III study of KW-2246 (A double blind study of KW-2246 compared to placebo for breakthrough pain episodes in cancer patients)
Kyowa Hakko Kirin Co., Ltd.0 个研究点开始时间: 2011年3月30日最近更新:
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Written informed consent
- •- Have been treated with opioid analgesic on a fixed-schedule at a stable daily dose
- •- Receiving at least 1 but not more than 4 doses of rescue medication per day in average and whose pain is controlled
- •- ECOG PS =< 3
排除标准
- •- Currently suffered from intolerable opioid-specific adverse reactions due to opioid analgesics
- •- Ssevere respiratory dysfunction
- •- Severe bradyarrhythmia
- •- Severe hepatic function disorder
- •- Severe renal function disorder
- •- Severe psychoneurotic disorder
- •- Susceptibility to respiratory depression due to such conditions as increased intracranial pressure, head injury or brain tumor
研究者
相似试验
已完成
3 期
A Comparative Study of KW-2246Cancer Related Pain (Breakthrough Pain)NCT01326689Kyowa Kirin Co., Ltd.42
已完成
3 期
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer PatientsPain, CancerNCT00684632Kyowa Kirin Co., Ltd.51
已完成
3 期
A Phase III Clinical Study of KW-2246Pain, CancerNCT00683995Kyowa Kirin Co., Ltd.43
未知
3 期
Phase III clinical study of DQ-2466 -Double-blind controlled study of fixed-dose and up-titration DQ-2466 regimens in subjects with persistent or permanent atrial fibrillationPersistent or permanent atrial fibrillationJPRN-jRCT2080222155DAIICHISANKYO Co.,Ltd.120
未知
3 期
Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 (6500-004)Parkinson's DiseaseJPRN-jRCT2080220980Kyowa Hakko Kirin Co., Ltd.20